CYTKCytokinetics, Incorporated
$61.22+3.8% 1Y
$61.22
$54.7652 weeks$87.24
Is the price fair?
What CYTK's price assumes
Cytokinetics, Incorporated did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 126× revenue.
126
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 113
EV / sales
Details›
- EV / EBIToperating margin −1046%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 113
- Market capitalisation139.0 million shares, counted Aug 4, 2026
- $8.51B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks